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ABSTRACT 23 
Transition metals are co-factors for a wide range of vital enzymes, and are directly or indirectly 24 
involved in the response against reactive oxygen species (ROS), which can damage cellular 25 
components. Their altered homeostasis has been studied in neurodegenerative disorders such as 26 
Alzheimer’s disease (AD), Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS), but 27 
no data are available on rarer conditions.  28 
We aimed at studying the role of essential trace elements in Ataxia-Telengiectasia (A-T), a rare 29 
form of paediatric autosomal recessive cerebellar ataxia with altered antioxidant response. We 30 
found an increased level of copper (Cu, p=0.0002), and a reduced level of zinc (Zn, p=0.0002) in 31 
the blood of patients (n. 16) compared to controls, using inductively coupled plasma mass 32 
spectrometry (ICP-MS). Other trace elements involved in the oxidative stress response, such as 33 
manganese (Mn) and selenium (Se) were unaltered. Cu/Zn-dependent superoxide dismutase 34 
(SOD1) was shown to have a 30% reduction in gene expression and 40% reduction in enzyme 35 
activity upon analysis of lymphoblastoid cell lines of patients (Student’s t-test, p=0.0075). We also 36 
found a 30% reduction of Mn-SOD (SOD2; Student’s t-test, p=0.02), probably due to a feedback 37 
regulatory loop between the two enzymes. The expression of antioxidant enzymes, such as 38 
erythrocyte glutathione peroxidase (GPX1), and SOD2 was unaltered, whereas catalase (CAT) was 39 
increased in A-T cells, both at the mRNA level and in terms of enzyme activity (~25%). Enhanced 40 
CAT expression can be attributed to the high ROS status, which induces CAT transcription. 41 
These results suggest that alterations in essential trace elements and their related enzymes may play 42 
a role in the pathogenesis of A-T, although we cannot conclude if altered homeostasis is a direct 43 
effect of A-T mutated genes (ATM). Altered homeostasis of trace elements may be more prevalent 44 
in neurodegenerative diseases than previously thought, and it may represent both a biomarker and a 45 
generic therapeutic target for different disorders with the common theme of altered antioxidant 46 
enzyme responses associated with an unbalance of metals. 47 
48 
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INTRODUCTION 49 
Ataxia-Telangiectasia (A-T) is an autosomal recessive multisystem disorder with a frequency of 50 
1/40,000–1/100,000 (Swift et al., 1986). Main clinical features include progressive cerebellar 51 
degeneration leading to severe neuromotor dysfunction, oculocutaneous telangiectasia, profound 52 
immunodeficiency of both humoral and cellular compartments, gonadal dysgenesis, growth 53 
retardation in some patients, predisposition to malignancies (primarily lymphoreticular), high levels 54 
of serum alpha-fetoprotein, and acute radiosensitivity. A-T cells show chromosomal instability, 55 
premature senescence, accelerated telomere shortening, sensitivity to the cytotoxic and clastogenic 56 
effects of ionizing radiation and radiomimetic chemicals, and defective activation of cell-cycle 57 
checkpoints by these agents (Boder and Sedgwick, 1970; Gatti, 2001; Shiloh, 2006). The A-T 58 
mutated gene (ATM) encodes for a serine/threonine protein kinase recruited and activated by DNA 59 
double-strand breaks. ATM phosphorylates several key proteins that initiate the activation of DNA 60 
damage checkpoints, leading to cell cycle arrest, DNA repair or apoptosis. Although the 61 
neurodegenerative phenotype has been attributed to a defective response to DNA breaks in pre- and 62 
post-mitotic neurons (Lee et al., 2001), oxidative stress and reduced anti-oxidant defence may also 63 
play a role (Biton et al., 2006).  64 
Correlation of the A-T phenotype with oxidative stress has been determined by molecular, in vitro 65 
and animal studies. A-T patients show persistent oxidative stress at the cellular level, and ATM 66 
knock-out mice exhibit increased signatures of reactive oxygen species (ROS) (Chen et al., 2003; 67 
Kamsler et al., 2001; Liu et al., 2005; Watters, 2003). At the molecular level, persistent oxidative 68 
stress in A-T cells was recently associated with the activation of ATM in response to oxidants (Guo 69 
et al., 2010), a mechanism clearly distinct from activation by DNA breaks. Therefore, ATM plays a 70 
role in redox-sensing and signalling, and the loss of redox balance in A-T may be central to the 71 
neuro-pathological phenotype. Several reports have demonstrated the protective effects of low 72 
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molecular weight antioxidants on the A-T phenotype (Browne et al., 2004; Reliene et al., 2008; 73 
Reliene and Schiestl, 2007).  74 
Multiple antioxidant defence systems are present in the human body to escape the damage caused 75 
by reactive oxygen species (ROS). Superoxide dismutase (SOD) acts by degrading the superoxide 76 
anion (O2·-), while catalase (CAT) and glutathione peroxidase (GPx) detoxify hydrogen peroxide 77 
(H2O2). Trace elements are required in small concentrations as essential cofactors for the 78 
antioxidant enzymes. GPx, cytoplasmic Zn/Cu-SOD (SOD1), mitochondrial Mn-SOD (SOD2) and 79 
CAT enzymes contain Se, Zn/Cu, Mn and Fe as cofactors, respectively.  80 
Trace metals therefore play important roles in a wide variety of biological processes, and their 81 
altered homeostasis has been implicated in the aetiology of several neurodegenerative disorders 82 
(Bush, 2003; Jellinger, 2013). Metals interfere with cell signalling pathways and affect growth 83 
receptors, tyrosine and serine/threonine kinases, as well as nuclear transcription factors, by reactive 84 
oxygen species (ROS)-dependent and ROS-independent mechanisms. In neurodegenerative 85 
disorders, it is now recognized that the main underlying cause is increased oxidative stress, 86 
substantiated by the findings that the protein side-chains are modified either directly by ROS or 87 
reactive nitrogen species (RNS), or indirectly, by the products of lipid peroxidation. Hydroxyl 88 
radical (OH.) is the primary ROS implicated in neurodegenerative stress, and although peroxynitrite 89 
appears to be capable of hydroxyl-like activities, hydroxyl radicals mostly reflect the Fenton 90 
reaction between reduced transition metals, usually iron or copper, and hydrogen peroxide (H2O2) 91 
(Taddeo et al., 2003). 92 
In Alzheimer’s disease, the increased level of oxidative stress in the brain is reflected by elevated 93 
levels of iron (Fe) and copper (Cu) in the brain, both of which are capable of stimulating free 94 
radical formation via the Fenton reaction (Jomova et al., 2010). 95 
Breakdown of metal-ion homeostasis can lead to metals binding to protein sites which are not 96 
intended for metal-binding, replacement of other metals from their natural binding sites (Nelson, 97 
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1999), or to uncontrolled metal-mediated formation of deleterious free radicals (Gutteridge, 1995; 98 
Valko et al., 2007). In particular, essential trace elements such as copper, zinc and manganese, play 99 
a major role in metabolic pathways, and they have been studied in many diseases, including 100 
autoimmune, neurological and psychiatric disorders.  101 
Currently, only scarce information is available, on in vivo redox abnormalities in A-T patients 102 
(Aksoy et al., 2004; Reichenbach et al., 2002; Reichenbach et al., 1999).  103 
Here, we have studied the blood concentration of trace elements in A-T patients. We further 104 
explored the expression of CAT, GPX1, SOD1 and SOD2, and the activity of CAT, SOD1 and 105 
SOD2 enzymes in A-T lymphoblastoid cell lines, to verify if changes in the metal concentration 106 
correlate with antioxidant enzyme activity, which is probably secondary to the alterations in their 107 
cofactor concentrations. 108 
 109 
MATERIALS AND METHODS 110 
Patients 111 
We enrolled 16 A-T patients (9 males and 7 females; median age 10.6 years, range 3-23 years) 112 
diagnosed with A-T according to the diagnostic criteria of the European Society for 113 
Immunodeficiencies (ESID), and subsequently confirmed by genetic testing. None of the patients 114 
had acute infections at the time of sample collection. The control group consisted of 18 healthy 115 
individuals (10 males and 8 females, median age 13.2, age range 3-23 years old). The study was 116 
carried out in accordance with the ethical standards specified in the 1964 Declaration of Helsinki, 117 
and was approved by the internal review board of the Department of Medical Sciences (DSM-118 
ChBU). Informed consent was obtained from patients or their legal representative. 119 
 120 
Blood sampling and analysis of metals 121 
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Venous blood was collected in heparinized vacutainer BD tubes (Becton Dickinson Labware, 122 
Franklin Lakes, USA), and stored at -20°C until required for analysis. A sub-aliquot of 1 mL of 123 
blood was transferred into a 15 mL plastic tube (Falcon, Becton, Franklin Lakes, USA), then added 124 
to 2mL of super-pure concentrated HNO3 (Romil Ltd., Cambridge, UK) and microwave (MW) 125 
digested in an ETHOS-Mega II oven (FKV, Bergamo, Italy), following the temperature ramp 126 
program: 45 min to reach 100°C and 4 h at 100°C. The system was equipped with an optical sensor 127 
to regulate the temperature. In each digestion, a blank reagent and a blood certified reference 128 
material was also processed (Seronorm trace elements whole blood level 2, Sero AS, Billingstadt, 129 
Norway).  130 
 131 
Instruments 132 
A Thermo X series II ICP-MS instrument (Thermo Scientific, Germany), with interface Ni sampler 133 
and skimmer cone, was equipped with a CETAC ASX 500 Model 520 (CETAC Technologies, 134 
USA) auto sampler and a peristaltic pump nebulizer. 135 
Operating conditions were as follows: forward power 1.40 kW, coolant gas flow rate 13.0 L/min, 136 
auxiliary gas flow rate 0.70 L/min, nebulizer gas flow rate 0.90 L/min, dwell time 10 ms, with five 137 
replicates. Torch position, ion lenses and gas output were optimized daily with a tuning solution. 138 
The Collision Cell Technique (CCT), performed with a Helium/Hydrogen mixture (95/5) at a flow 139 
rate of 3.5 ml/min, was used to remove interferences. 140 
An ETHOS 1 microwave digestion system (Milestone S.r.l, Italy) was used for acid digestion of 141 
cereals and reference materials. The recoveries are shown in Table S1. The Limit Of Quantification 142 
(LOQ) is the lowest concentration of the analyte that can be correctly quantified in the sample. The 143 
percentage of recovery (range 80-120) is determined by dividing the value observed in the 144 
analytical procedure by the reference value of the Reference Material (Table S1).  145 
 146 
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 148 
Table S1. Quantification limit values (µg/L), reference material values and 
percentages of recovery. 
Element LOQ 
Seronorm trace elements 
whole blood level 2 
Percentage of  
recovery 
As 10 14.3±2.9 107 
Be 5 5.68±0.23 108 
Cd 5 5.8±0.2 105 
Co 5 5.8±1.2 90 
Cr 10 11.8±2.4 108 
Cu 10 1,330±270 109 
Fe 100 331,000±17,000 106 
Mn 10 29.9±6.0 103 
Ni 20 17.9±3.6 n.a. 
Pb 10 310±62 102 
Sb 10 30.5±6.1 92 
Se 10 112±23 98 
Sn 10 5.7±1.2 n.a 
Tl 10 10.3±0.3 90 
Zn 100 6,500±300 90 
Note: n.a: not applicable because <LOQ 
 149 
Cell culture 150 
Five A-T lymphoblastoid cell lines (LCLs) were obtained from blood samples of patients by 151 
Epstein-Barr virus (EBV) infection (Table S2). Six gender-matched control LCLs were obtained 152 
from the Human Genetics Foundation of Torino (HuGeF). LCLs were grown at 37°C and 5% CO2 153 
in RPMI-1640 medium supplemented with 10% heat-inactivated foetal bovine serum, 2 mM L-154 
glutamine, 0.1 mg/ml streptomycin and 100 U/ml penicillin. 155 
Table S2.  ATM mutations at protein level in tested cell lines.  
Gender Protein change  
M p.[(Arg2506fs)];[(Arg2506fs)]  
F p.[(Trp2109*)];[(Trp412*)]  
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F p.[(Ser1037fs;Lys2643_Lys2671del)];[(p.Trp1814)]  
F p.[(Met2938fs)];[(*3057Glyext*28)]  
M p.[(Met1_Pro938dup)];[(Arg62_Arg111del)]  
 156 
Gene expression 157 
Total RNA was extracted using Direct-zol according to the manufacturer's protocol (Zymo 158 
Research Corporation, Irvine, USA); one milligram was retro-transcribed using M-MLV Reverse 159 
Transcriptase (Life Technologies Europe, Monza, Italy). Quantitative real-time RT-PCR to evaluate 160 
CAT, GPX1, SOD1 and SOD2 expression was carried out on an ABI-Prism7500 Fast instrument 161 
(Life Technologies, Europe) using the TaqMan® Universal PCR Master Mix, Universal Probe 162 
Library (UPL) technology (Roche Diagnostics, Mannheim, Germany) (Table S3). 163 
 
Table S3. Primers and probes used for gene expression analysis by real-time qPCR 
Assay Primer F Primer R UPL probe 
CAT 5’-gctcattttgaccgagagaga 5’-tgacctcaaagtagccaaagg #68 
GPX1 
SOD1 
5’-caaccagtttgggcatcag 
5’-tcatcaatttcgagcagaagg 
5’-tctcgaagagcatgaagttgg 
5’-gcaggccttcagtcagtcc 
#77 
#60 
SOD2 5’-ctggacaaacctcagcccta 5’-tgatggcttccagcaactc #22 
 164 
Experimental Ct values were normalized to the human GUSB gene (beta glucuronidase) or TBP 165 
(TATA-binding protein) Endogenous Controls (VIC®/TAMRA Probe, Life Technologies Europe). 166 
Gene expression was calculated in each sample relative to the mean of controls, using the delta-167 
delta Ct method as described (Livak and Schmittgen, 2001). Each sample was examined in 168 
triplicate.  169 
 170 
Analysis of SOD isoforms activities 171 
A total of 1x107 cells, obtained from five A-T cell lines and four control cells, were collected and 172 
homogenized in lysis buffer (20 mM Hepes pH 7.2, 1 mM EGTA, 210 mM mannitol and 70 mM 173 
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sucrose). Cells were then centrifuged at 1,500 g for 5 min at 4°C. To separate the two enzymes 174 
(cytosolic and mitochondrial), supernatants were centrifuged at 10,000 g for 15 min at 4°C; the 175 
supernatant contained the cytosolic SOD, whereas the pellet was washed and resuspended in ice 176 
cold lysis buffer to measure mitochondrial SOD. To evaluate SOD activities in the two lysates, we 177 
used the Superoxide Dismutase Assay kit (Cayman, MI, USA, #706002). Analysis was performed 178 
by reading the absorbance at 440-460 nm on the microplate Reader, Model 680 (Bio-179 
Rad Laboratories S.r.l., Segrate, Italy). To obtain SOD activity quantification, we compared 180 
absorbance values to a Standard curve with the range 0-0.25 U/mL of the SOD standard (assayed in 181 
each experiment in triplicate). Each sample was assayed in duplicate and in at least three 182 
independent experiments. 183 
 184 
Analysis of CAT activity 185 
The day of the experiment, a total of 5x106 cells, obtained from three A-T cell lines and three 186 
control cells, were collected by centrifugation, washed twice in PBS and homogenized in ice cold 187 
lysis buffer (50 mM potassium phosphate, 1 mM EDTA, pH 7.0). Cells were centrifuged at 10,000 188 
g for 15 minutes at 4°C. Supernatant was stored on ice for the assay. To evaluate CAT activities, we 189 
used the Catalase Assay kit (Cayman, MI, USA, #707002) following manufacture’s protocol. 190 
Analysis was performed by monitoring the absorbance at 540 nm on a xMark microplate Reader 191 
(Bio-Rad Laboratories S.r.l., Segrate, Italy). CAT activity was defined as the amount of CAT 192 
enzyme able to produce 1.0 nmol of formaldehyde per minute at 25°C, interpolating the values in a 193 
standard curve of formaldehyde ranging 0-75 µM. Each sample was assayed in duplicate and in at 194 
least three independent experiments. 195 
 196 
Statistical analysis 197 
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For analysing metal concentrations, we performed the D’Agostino-Pearson normality test to 198 
determine the distribution of the values. Mean values of variables with normal distribution were 199 
reported, and comparison between control group and the patient group was conducted using the 200 
Student’s t-test. If the distribution of data was not normal, variables were presented as median 201 
values (Cr, Fe, Mn, Cu, Se and Zn) and differences between the two groups were studied using the 202 
Mann-Whitney U test. The median concentration of each quantifiable element is shown with its 203 
standard deviation. Results were considered statistically significant at p values of < 0.01. 204 
Significance of gene expression and enzyme activity data was calculated using the Student’s t-test 205 
(unpaired). Statistical calculations were performed using Graph Pad Statistics Software Version 6.0 206 
(GraphPad Software, Inc., USA). 207 
 208 
RESULTS 209 
We measured whole blood concentration of 15 metals in A-T patients and healthy controls by using 210 
ICP-MS (Table 1).  211 
Table 1. Median concentration of metals (g/L ± S.D) in the blood of A-T 
patients and controls. 
Metals 
 
Patients  
(N=16) 
Controls  
(N=18) 
P 
Cr 17.3 (±2.0) 20.7 (±3.5) 0.3201 
Cu  1,460 (±353) 935 (±260) 0.0002 
Fe 431,350 (±1,020) 425,271 (±2,015) 0.5011 
Mn  34.2 (±2.1) 39.0 (±1.4) 0.4787 
Se  110 (±50.8) 130 (±39.9) 0.2140 
Zn  4,370 (±435) 5,760 (±577) 0.0002 
     Note: In bold statistically significant metal ions. 212 
 213 
As, Be, Cd, Co, Ni, Pb, Sb, Sn and Tl levels were below the limit of quantitation of the method. 214 
Copper levels were significantly higher in A-T patients (p = 0.0002) and zinc levels were 215 
significantly lower (p = 0.0002). As copper and zinc are co-factors for ROS detoxifying enzymes, 216 
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we measured the activity of cytosolic (Cu/Zn-isoform, SOD1), mitochondrial superoxide dismutase 217 
(Mn-isoform, SOD2) and catalase (CAT) by ELISA assay in A-T LCLs. We showed a 40% 218 
reduction of Cu/Zn-SOD isoform activity (A-T median dose: 0.66 ± 0.06 U/ml; n = 5  vs. CTRLs 219 
median dose: 1.0  ±  0.09 U/ml; n = 5; Student’s t-test, p = 0.0075) and a 30% reduction of Mn-220 
SOD (A-T median dose: 0.67 ± 0.08 U/ml; n = 5  vs. CTRLs median dose: 1.1 ± 0.13 U/ml; n = 5; 221 
Student’s t-test, p = 0.02). CAT activity was increased by ~25% in patients’ cells compared to 222 
controls (A-T mean dose: 1.24 ± 0.08; vs. CTRLs mean dose: 1.0 ± 0.8; Student’s t-test, p = 0.039) 223 
(Figure 1A). 224 
Considering the feedback regulatory loop of detoxifying enzymes, we measured the expression of 225 
the same genes and GPX1 involved in the ROS response. Using real-time quantitative PCR, we 226 
showed a decreased SOD1 mRNA level in A-T cells vs. CTRLs (A-T median dose: 0.7  ± 0.03; n = 227 
4. CTRLs median dose: 1.0 ± 0.05; n = 4) (Student’s t-test, p = 0.0001). GPX1 and SOD2 showed 228 
levels similar to healthy controls (GPX1: A-T median dose: 0.95 ± 0.04; n = 5  vs. CTRLs median 229 
dose: 1.1 ± 0.08; n = 5; Student’s t-test,  p = 0.02, data not shown. SOD2: A-T median dose: 1.1 ± 230 
0.06; n = 5 vs. CTRLs median dose: 1.0 ± 0.03; n = 5; Student’s t-test, p = 0.10). Catalase mRNA 231 
level was increased in A-T cells vs. CTRLs (A-T median dose: 1.5 ± 0.09; n = 5  CTRLs median 232 
dose: 1.0 ± 0.07; n=5) (Student’s t-test,  p = 0.0012) (Figure 1B).  233 
 234 
DISCUSSION 235 
The current knowledge in the field of neurodegenerative diseases indicates that metal-induced and 236 
metal-enhanced formation of free radicals and other reactive species can be regarded as a common 237 
factor in determining toxicity induced by metals (Jomova et al., 2010). Many reports link the origin 238 
of Alzheimer’s disease (AD), and to a lesser extent Parkinson’s disease (PD), to increased oxidative 239 
stress of the brain. A role for metals in these diseases and other disorders, such as Huntington’s 240 
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disease, amyotrophic lateral sclerosis, and prion diseases such as Creutzfeldt-Jakob disease has been 241 
proposed (Bush and Curtain, 2008; Jomova et al., 2010).  242 
We focused our attention on a rare form of paediatric ataxia, Ataxia-Telangiectasia, because of our 243 
interest in the genetics and molecular pathogenesis of this disease (Cavalieri et al., 2008; Cavalieri 244 
et al., 2006; Cavalieri et al., 2012). Among the pleiotropic features of A-T, neurodegeneration and 245 
premature aging are strongly associated with accumulation of oxidative damage which may 246 
contribute to degenerative processes observed in this disease (Reichenbach et al., 2002). In vitro, A-247 
T cells are under a constant state of oxidative stress with high ROS levels, and have an abnormal 248 
response to agents inducing oxidative stress (Watters, 2003). Several groups have documented the 249 
presence of high levels of oxidative damage in A-T patients, confirming previous observations 250 
made in Atm-/- mice which displayed increased levels of oxidative stress and damage (Hoche et al., 251 
2012; Kamsler et al., 2001; Schubert et al., 2004; Stern et al., 2002). In fact, brains or astrocytes 252 
from Atm-deficient mice present high ROS levels and an increased activation of the ERK1/2 redox-253 
sensitive kinases (Liu et al., 2005). (Reliene and Schiestl, 2007) showed that the antioxidant N-254 
acetylcysteine suppresses ERK signalling and protects Purkinje cells from oxidative stress-induced 255 
degeneration in Atm-deficient mice. Furthermore, (Stern et al., 2002) found a significantly impaired 256 
level of nicotinamide adenine dinucleotide phosphate, a cofactor of antioxidant enzymes, in 257 
cerebellar neurons of Atm-/- mice. Developing neurons are rapidly proliferating and potentially able 258 
to accumulate high levels of oxidants; therefore the above data provide extensive evidence that at 259 
least a part of the neurological phenotype in A-T may result from ROS-deficient homeostasis 260 
(Hoche et al., 2012). 261 
We found increased copper and reduced zinc levels in the blood of A-T patients. Alterations in 262 
copper levels may reflect many physiological and pathological conditions, including dietary factors, 263 
hepatic disease, and acute and chronic infections, or it may be suggested they are associated directly 264 
with ATM impairment.  265 
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Copper is toxic when present in excessive amounts as it can directly induce ROS production, 266 
through Fenton and Haber-Weiss reactions (Halliwell, 2006). Therefore, free Cu levels must be 267 
precisely regulated in the cell in order to minimize damage. The excess of Cu reported in A-T 268 
patients may promote free radical-mediated pathways that, in turn, give rise to an antioxidant 269 
response. In our patients, an increase in mRNA and activity of catalase may represent the first 270 
process to escape an excess of ROS. However, this response seems to be insufficient.  271 
Indeed, maintenance of appropriate copper levels in neurons is critical for their correct development 272 
and/or function; specifically, release of copper into the synaptic cleft regulates the excitability of 273 
neurons and also helps protect the neurons from excitotoxicity (Marmolino and Manto, 2010).  Cu 274 
dyshomeostasis has been related to neurodegenerative disorders such as Alzheimer’s, and 275 
amyotrophic lateral sclerosis (ALS), and it is directly involved in Mendelian disorders such as 276 
Wilson and Menkes diseases (Ahuja et al., 2014).  277 
Cu is also an essential component of Complex IV of the mitochondrial respiratory chain and part of 278 
the ROS scavenging cell repertory, being a co-factor of the superoxide dismutase isoform present in 279 
the cytosol (Cu/Zn-SOD or SOD1). SOD1 is the predominant superoxide dismutase in most cells 280 
and tissues, accounting for 70–80% of the total cellular SOD activity. Its primary function is to act 281 
as an antioxidant enzyme, lowering the steady-state concentration of superoxide. Over 100 different 282 
mutations have been identified in the SOD1 gene in patients diagnosed with the familial form of 283 
AML (Valentine et al., 2005).  284 
An equilibrated molar ratio between Cu and Zn is essential for correct function of SOD1. In the 285 
presence of a Cu/Zn unbalance, equimolar Cu/Zn-SOD rapidly forms heterodimers with Zn-286 
deficient SOD leading to SOD1 deficiency. The stabilization of Zn-deficient SOD with Cu/Zn-SOD 287 
has been suggested to contribute to the dominant inheritance of ALS mutations (Roberts et al., 288 
2007). We suggest that the impaired molar ratio of Cu/Zn seen in A-T patients may be the basis of 289 
the SOD1 functional reduction in A-T cells.  290 
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Eukaryotic systems have evolved defence mechanisms against free radicals and the manganese 291 
superoxide dismutase (Mn-SOD or SOD2) is a key mitochondrial antioxidant enzyme, coded by the 292 
SOD2 gene, which catalyses the conversion of superoxide anions to hydrogen peroxide (Flynn and 293 
Melov, 2013). Loss of SOD2 activity can result in numerous pathological phenotypes in 294 
metabolically-active tissues, particularly within the central nervous system. SOD2 is  potentially 295 
involved in the progression of neurodegenerative diseases, such as stroke and Alzheimer’s and 296 
Parkinson’s diseases, as well as its potential role in “normal” age-related cognitive decline (Clausen 297 
et al., 2010). In this study, we found that blood manganese concentrations were comparable in 298 
patients and controls, although SOD2 enzyme activity assays showed a 30% decrease in 299 
comparison to the control group. 300 
Conversely, reduction of zinc may lead to several deleterious effects. The decrease of Zn 301 
concentrations in the blood could be a result of Zn accumulation in tissues, along with dietary 302 
factors. Zinc is an essential metal implicated in the functioning of more than 200 enzymes; it plays 303 
an important role in axonal and synaptic transmission and is necessary for nucleic acid metabolism 304 
and brain tubulin growth and phosphorylation. In physiological concentrations, zinc exhibits 305 
neuroprotective activity, although an unbalance of zinc homeostasis has been reported in a number 306 
of brain processes, which can then lead to the onset of chronic pathologies such as depression, 307 
schizophrenia, AD, PD, aging, or ALS (Szewczyk, 2013). High concentrations of zinc are 308 
neurotoxic (Choi et al., 1988; Cote et al., 2005; Perry et al., 1997; Plum et al., 2010), and its 309 
deficiency has been reported in the plasma of AD patients, and it is hypothesized that a deficiency 310 
of Zn could be one of the contributing factors in the development of AD (Constantinidis, 1991; 311 
Religa et al., 2006).  312 
It is interesting to note that many A-T patients display a primary immunodeficiency, and zinc 313 
deficiency may play a role in modulating this phenotype (Lynn and Wong, 1997; Prasad et al., 314 
2007). Zinc is essential for the maintenance of immune function and for the development and 315 
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function of neutrophils, macrophages, and natural killer cells. Thus, zinc deficiency leads to the 316 
reduction of thymulin, interleukin-2, and interferon-gamma, and the increase in production of pro-317 
inflammatory cytokines: zinc deficiency is also associated with a higher incidence of infections.  318 
A hypothesis for the protective role of antioxidants considers the induction of synthesis of 319 
metallothioneins (MTs). These proteins contain a large number of thiol groups, which are effective 320 
in the reduction of ROS formation (Valko et al., 2005). MTs are zinc-binding proteins involved in 321 
the regulation of the transport, storage and transfer of zinc to various enzymes and transcription 322 
factors (DiGirolamo et al., 2010; Liuzzi and Cousins, 2004).   323 
Finally, similarly to our findings, zinc was found to be significantly reduced in the plasma of 324 
children with Type 1 Diabetes Mellitus (T1DM) (Salmonowicz et al., 2014), the activity of SOD1 325 
was significantly reduced and CAT activity was significantly increased. (Shukla et al., 2006) 326 
proposed that in diseases associated with chronic oxidative stress, ROS impair the Cu/Zn-SOD 327 
function by reducing intracellular Cu ions found in protein compounds such as metallothionein and 328 
SOD.   329 
 330 
CONCLUSIONS 331 
Mutations that inactivate wide-ranging regulators such as ATM, the gene mutated in A-T, are 332 
expected to affect many cellular systems and cause serious disruption of cellular homeostasis. The 333 
clinical and cellular phenotypes of such disorders also indicate ongoing deleterious processes, 334 
marked by slowly progressing degeneration of specific tissues and occasionally by signs of 335 
premature aging. A possible contributor to these processes, which are also seen in various 336 
neurodegenerative diseases and aging tissues, is oxidative stress, reflected by elevated levels of 337 
ROS. A-T cells show poor cellular anti-oxidant defences and increased oxidant sensitivity 338 
compared to normal cells, and ATM partly functions as an oxidative stress sensor. Accumulating 339 
evidence suggests that oxidative stress is involved in the pathogenesis of A-T.  340 
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In line with these observations, we detected alterations in the essential trace elements copper and 341 
zinc, which are involved in the oxidative-stress response, in the blood of A-T patients, which was 342 
associated with transcriptional and functional alterations of ROS-detoxifying enzymes (CAT, SOD1 343 
and SOD2) in patients’ cell lines.  344 
Our results suggest that zinc and copper homeostasis may play a role in the pathology of A-T, as 345 
summarized in figure 2. The initial determinant of the dyshomeostasis of these metals is unknown, 346 
and may be ATM deficiency itself. In turn, they contribute to an altered antioxidant defence system, 347 
impairing SOD1 and SOD2 activity. Enhanced catalase expression is a marker of increased ROS 348 
activity. Indeed Zn depletion, due to its antioxidant properties, may act to further increase oxidative 349 
damage.  350 
Cu/Zn alterations may therefore be suggested as biomarkers of A-T, and open to future works on 351 
other ataxias of genetic origin. Furthermore, given the unbalance and the antioxidant properties of 352 
Zn, dietary supplementation with this metal, which has also been proposed in other studies (Bao et 353 
al., 2008; Prasad et al., 2007), would be an interesting therapeutic possibility that should be 354 
explored in future experiments. 355 
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FIGURE LEGENDS 364 
Figure 1. Enzymatic activity and expression analysis of ROS-detoxifying enzymes in A-T 365 
lymphoblasts. A. In the upper panels, enzymatic activity of the related proteins was measured by 366 
ELISA assay and expressed as relative activity vs. controls (Superoxide Dismutase Assay kit, 367 
Cayman, MI, USA, and Catalase Assay kit, Cayman, MI, USA, #707002). CAT showed a 20% 368 
increase in activity in A-T patients. Both SOD1 and SOD2 enzymes showed a reduced activity of 369 
30-40% in A-T cell lines (* = p < 0.05; ** = p < 0.01). B. In the lower panels, expression of CAT, 370 
SOD1 and SOD2 genes was tested by real-time PCR. Reference genes for normalization were 371 
GUSB for CAT, and SOD2 and TBP for SOD1. Fold-changes were significant for CAT and SOD1 372 
genes and concordant with activity (* =  p<0.05). CTRLs: controls; A-T: Ataxia-Telangiectasia 373 
patients. 374 
 375 
Figure 2. Schematic summary of the role of Cu and Zn metals in A-T cells. A Cu/Zn unbalance, 376 
which may be directly associated with ATM mutations, or secondary to unknown causes, can affect 377 
A-T cell survival by increasing ROS directly via Cu oxidative damage, and by SOD1/SOD2 378 
impairment. ROS increase induces a higher CAT transcription in the attempt to reduce ROS stress. 379 
 380 
381 
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